EZH2的酸化不同于HER2阳性乳腺癌的侵袭性,以特定地点的方式
Feng Yu1, Lili Li2, Mengwen Zhang3
1Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, Ministry of Education, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Cancer Institute, Zhejiang University, Hangzhou, 310058, Zhejiang, China.
BMC cancer
|October 6, 2023
概括
高EZH2表达预测了侵袭性乳腺癌 (BC). 化EZH2在核中的S21可能预测HER2-阳性BC和治疗反应不佳.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 由于侵袭性和耐药性,HER2阳性乳腺癌 (BC) 存在重大挑战.
- EZH2在BC进展中的作用及其依赖酸化的功能需要进一步阐明.
研究的目的:
- 调查HER2-阳性BC中总和酸化EZH2的表达模式和临床意义.
- 探索EZH2酸化位点作为BC侵入性和治疗反应的生物标志物的潜力.
主要方法:
- 在BC数据库和组织微阵列中分析EZH2总和酸化形式.
- EZH2表达和定位与临床阶段,淋巴结转移和HER2状态的相关性.
主要成果:
- EZH2在BC细胞的核和细胞质中表现出酸化位点特定的局部化.
- 高EZH2表达与BC的晚期临床阶段和淋巴结转移有关.
- 位于核中的pEZH2-S21与侵袭性和转移性HER2-阳性BC相关.
- 细胞质pEZH2-T487与HER2阳性状态有关.
结论:
- 核EZH2表达可能预测侵入性BC.
- 核中的激活的pEZH2-S21可以作为HER2-阳性BC的生物标志物,并预测对HER2-向治疗的耐药性.
- 这些发现表明,EZH2在HER2阳性BC中具有PRC2独立的非表观遗传作用,这为潜在的新治疗策略提供了机会.
相关概念视频
Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K


